Federico Iovino has been awarded 1.2 million DKK (approximately 1.7 million SEK) to address antimicrobial resistance. His project, titled "Development of dual endolysins as next-generation treatments for antibiotic-resistant bacterial infections," focuses on Streptococcus pneumoniae, a primary cause of bacterial meningitis.
The research explores phage-derived endolysins, which are enzymes capable of eliminating antibiotic-resistant bacteria and neutralizing toxins that damage brain tissue.
Federico Iovino, an Associate Professor and research group leader at the Department of Neuroscience, indicated that antimicrobial resistance could become the world's leading cause of death by 2050. He stated that developing new treatments is critical due to the limitations of traditional antibiotics.
Brain infections pose a specific challenge, as neurons damaged during infection cannot be repaired even after bacteria are eradicated. This leaves survivors susceptible to lifelong complications, including motor disabilities and cognitive impairment.
Iovino's work aims to develop therapies that not only combat infection but also protect the brain and preserve neurological functions.